SILVER SPRING·MAY 16, 2026 RTF
Harper Tx receives Refuse-to-File on lead BTK inhibitor; cites incomplete pivotal QC package
CMC and clinical data lock timing flagged. Resubmission window narrows to Q4.
→
Latest dispatch MAY 17, 2026
COMMENTARY BOSTON·MAY 17, 2026
When the agency calls back: reading the new wave of CRLs as a methodology question
The latest FDA tranche of Complete Response Letters reads less like a string of individual misses and more like an audit of how sponsors plan oversight. A close read of the pattern.
/ 12 min read / Inspection Readiness
DATELINE HEADLINE AUTH · LEN
CAMBRIDGE·MAY 15, 2026 TOPLINE
Karuna Therapeutics announces positive topline data for KAR-201 in schizophrenia Phase III
Primary endpoint met at week 12; key secondary endpoints separated from placebo. BLA filing on track for H2 2026.
→
SILVER SPRING·MAY 14, 2026 CRL TRANCHE
FDA releases tranche of redacted CRLs spanning oncology, neuro, and rare disease NDAs
Eight letters released under FOIA; recurring citations on monitoring oversight and protocol deviation handling.
→
AMSTERDAM·MAY 12, 2026 GUIDANCE READ
EMA Reflection Paper on risk-based quality management: what changed between the draft and the final
Three substantive shifts that change how sponsors should structure their RBQM plans. We diff the 2024 draft against the May 2026 final.
9 min →
SILVER SPRING·MAY 10, 2026 ADCOMM
Advisory Committee votes 12–4 in favor of NorthLake's ALS therapy; pivotal trial conduct gets specific praise
Reviewers cited the sponsor's pre-specified deviation handling and inspection-ready monitoring as factors in their vote.
→
TOKYO·MAY 09, 2026 INSPECTION
PMDA issues two GCP citations following pivotal trial inspection of mid-stage oncology sponsor
Sponsor oversight of investigator-led data correction process flagged as primary observation.
→
BOSTON·MAY 08, 2026 PRIMER
Open-book test: a primer on building ICH E6(R3) expectations into trial design from day one
The methodology in 1,800 words. Why the agencies tell you exactly what they'll ask, and how to design oversight that produces those answers without scrambling.
8 min →